Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual screening strategy

Cancer is the second leading cause of death worldwide. Among various anticancer drug targets, mTOR is noteworthy. Numerous first-generation mTOR inhibitors are already approved and few second-generation mTOR inhibitors targeting the kinase domain are in the clinical trials, but yet to reach the market, and many lead to serious toxicities. Here we are focused to discover some novel kinase inhibitors from the ZINC database which may effectively inhibit mTOR kinase. For this, computational chemistry and pharmacophore-based ZINC database search has been adopted. Series of virtual screening analysis lead to the discovery of 5 active hits. Among these 5, compound 4 (ZINC79476038) having binding energy of −8.9 Kcal/mol shows maximum interactions within the binding pocket. Study proved that all these compounds can potentially inhibit mTOR kinase and can be successfully developed as anticancer agents. We further proved that these compounds are not only active for general cancers like lung, breast, colon, and other peripheral cancers but also equally active in CNS, targeting numerous brain cancers.